PubMed Health⌕ Search

Biomedical subjects

D V Preobrazhenskiĭ

Publications and source records attributed to D V Preobrazhenskiĭ.

At least 19 recordsLinked to original sources
PubMed1995

[Use of bonnecor in the treatment of ventricular arrhythmia].

The effectiveness of the new antiarrhythmic drug bonnecor was tried in 59 patients with ventricular arrhythmia. High antiarrhythmic activity of the drug was recorded in the course doses 150 to 250 mg/day. Bonnecor effect is dose-dependent: the number of ventricular extrasystoles reduced by 75% in 62 and 74% of the patients receiving 150 mg/day and 20 mg/day, respectively. The highest effect was achieved in high-grade ventricular extrasystole. Side effects were occasional: headache lasting 1-2 hours 40-50 min after bonnecor administration, slow atrioventricular conduction (2 cases), sleep disorders (2 cases).

Adult↗
PubMed1994

[Ticlopidine].

Explore the source record for details and available documents.

Animals↗
PubMed1993

[The pharmacodynamics of the new anti-arrhythmia preparation bonnecor based on the data from an acute drug test].

The pharmacodynamics of the new antiarrhythmic agent bonnecor was studied in 33 patients with coronary heart diseases and ventricular arrhythmias in the acute drug test. The parenteral formulation of the drug (0.04-0.8 mg/kg) and its tablets were given to 23 and 27 patients, respectively. Bonnecor was found to be effective in suppressing ventricular premature contractions. Its intravenous and oral efficacy is 65 and 70%), respectively. During intravenous injection, the drug showed its antiarrhythmic effect on an average of 14 minutes later, lasting about 68 minutes. During oral administration, the action of the drug started 0.5 hour later and lasted 7.2 hours. Adverse reactions were rare. An echocardiographic study revealed its negative inotropic effect which is likely to be insignificant since there was no development or increase of heart failure in any of the examinees (including 8 patients with signs of Stage I-IIA circulatory insufficiency).

Adult↗
PubMed1989

[Apoprotein B: its plasma level and interaction with cultured fibroblasts].

To study the relationship between the ability of apolipoprotein B (apo B) to interact with LDL receptors and its blood concentration, enzyme immunoassay was used to measure serum apo B levels in 51 healthy donors, 84 patients with coronary heart disease (CHD), and 22 newborns. Employing the same serum samples, the binding of apo B to fibroblasts was determined by the enzyme immunoassay modified for cultured cells. The mean values of apo B concentrations were found to be 0.89 +/- 0.25 mg/ml in the donors, 1.29 +/- 0.51 mg/ml in CHD patients, and 0.57 +/- 0.19 mg/ml in the newborns, while the apo B binding to the cells amounted to 108.9 +/- 16.7, 141.5 +/- 43.6, and 55.0 +/- 24.6 ng/mg, respectively. The mean values of serum apo B binding in the healthy donors and CHD patients were shown to correspond to the concentration relationship of pure LDL interaction with LDL receptors. The findings suggest that higher plasma apo B concentrations in CHD patients cannot be explained by lowered ability of serum apolipoproteins B to interact with LDL receptors of the cells.

Adult↗
PubMed1987

[An immunoenzyme method of determining apoprotein B and its diagnostic value in ischemic heart disease].

Enzyme immunoassays were used to measure blood apoprotein B (apo-B), a major protein component of low-density lipoproteins, in 96 patients with coronary disease due to coronary atherosclerosis, 21 patients with angiographically intact coronary arteries, and 130 apparently normal individuals (donors). The results of serum apo-B measurements were correlated to the presence or absence of atherosclerotic coronary arterial lesions, the spread of coronary atherosclerosis, as evidenced by selective coronarography, and patients' sex and age. The measurement of serum apo-B may be helpful in early diagnosis of coronary disease, being particularly valuable in males below 50 years of age.

Adult↗